论文部分内容阅读
目的:探讨复方黄精口服液抗心衰疗效及其作用机制。方法采用蛋白印迹杂交技术对阿霉素致心衰大鼠用药前后心功能指标进行监测,并对心室肌中肌球蛋白轻链2(VMLC2)的含量进行定量分析。采用t检验及相关分析方法进行分析。结果阿霉素心衰模型组心室收缩压(LVSP)明显低于正常组,而心室舒张压(LVDP)则显著高于正常组,反映心室收缩、舒张功能的心室内压最大上升速率(±dp/dtmax)也显著低于正常对照组;与正常对照组相比,阿霉素心衰模型组的VMLC-2的相对含量显著减少了31.5%(P<0.01);复方黄精口服液大、中剂量组较阿霉素心衰模型组VMLC-2的相对含量分别增加26.1%、17.9%,有显著统计学差异(P<0.01),而复方黄精口服液小剂量组则增加4%,未见显著改善(P>0.05);VMLC-2的含量与LVSP、+dp/dtmax、-dp/dtmax呈显著正相关(P<0.01)。结论复方黄精口服液可以增加心衰心肌MLC2的表达,改善心功能。
Objective: To investigate the efficacy and mechanism of compound Huangjing Oral Liquid against heart failure. METHODS: Western blot hybridization was used to monitor cardiac function before and after administration of adriamycin in rats with heart failure, and the content of myosin light chain 2 (VMLC2) in ventricular myocytes was quantitatively analyzed. T-tests and correlation analysis methods were used for analysis. RESULTS: Ventricular systolic blood pressure (LVSP) in the adriamycin-induced heart failure model group was significantly lower than that in the normal group, while ventricular systolic diastolic pressure (LVDP) was significantly higher than that in the normal group, indicating the maximum rate of increase in ventriculo-systolic and diastolic ventriculum pressure (±dp). /dtmax) was also significantly lower than the normal control group; compared with the normal control group, the relative content of VMLC-2 in the adriamycin-induced heart failure model group was significantly reduced by 31.5% (P<0.01); the compound Huangjing oral liquid was large and medium The relative content of VMLC-2 in the dose group was 26.1% and 17.9% higher than that in the adriamycin-induced heart failure model group, respectively (P<0.01), while that in the small dose group of Huangjing Oral Liquid was increased by 4%. Significant improvement (P>0.05); VMLC-2 content was positively correlated with LVSP, +dp/dtmax, and -dp/dtmax (P<0.01). Conclusion Compound Huangjing Oral Liquid can increase the expression of myocardium MLC2 in heart failure and improve cardiac function.